have a clearer understanding of how compliant hospitals are becoming (4) . The avoidance of inappropriate revascularization is not the only revelation that was pointed out using the appropriate use criteria document. A study from Ontario, Canada showed that patients deemed appropriate for revascularization who underwent revascularization had a 39% reduction in the composite of death or recurrent acute coronary syndromes at 3 years compared to patients who did not undergo revascularization (4) . In this appropriate category, patients who did not undergo revascularization also had a mortality rate that was more than double that of patients who did undergo revascularization. Therefore, failing to treat these patients with coronary revascularization increased their risk and, even for patients who were judged to have uncertain appropriateness, there was a trend in favor of better outcomes with revascularization. The guidelines, which are based on evidence as much as possible, clearly influence the votes on the appropriate use criteria, and these will surely influence the decision making for patients with stable ischemic heart disease. The new guidelines make recommendations for therapy to mitigate risk but also recommendations for the evaluation of symptoms. The recommendation to perform catheterization in patients with ongoing symptoms despite guideline-directed medical therapy importantly includes the consideration of patient preference. Space limitations prevent further discussion of the guidelines but I encourage you to read the document.
Perhaps in the future diagnostic coronary arteriography may not be necessary because some form of computed tomography angiography or other noninvasive method may obviate the need for invasive catheterization. On the other hand, if we look at the realities of today as reflected by the recent report from the Cath PCI Registry of the National Cardiovascular Data Registry (5), we see that in 2010 and 2011 among NCDR participating hospitals there were 1,110,150 diagnostic catheterization only cases and 941,248 percutaneous interventions. About half of the patients with diagnostic catheterizations had a stress test performed; however, of those, only 1.7% underwent coronary computed tomography angiography. The diagnostic use of the coronary arteriogram is illustrated by the fact that, of more than a million patients undergoing diagnostic arteriography only, one-half either had no coronary disease or nonobstructive coronary disease. Certainly for other imaging modalities, a negative test is not equated with an inappropriate indication for the procedure. Invasive imaging is viewed by some as carrying a greater risk than noninvasive imaging, but among more than a million diagnostic catheterizations, I noticed that the fluoroscopy time, Ͻ5 min on average, and the contrast volume is just over 100 cc's. Any bleeding within 72 h was reported in one-half of 1% of patients undergoing diagnostic catheterization without STEMI. Virtually all diagnostic catheterizations can be performed as outpatient procedures.
Finally, my view is that the coronary arteriogram is a diagnostic test of value in many situations. The most pertinent, key messages regarding revascularization in the new guideline are, "prior to revascularization to improve symptoms, coronary anatomy should be correlated with functional studies to ensure lesions responsible for symptoms are targeted," and the new emphasis that the degree of ischemia is a very potent predictor of cardiac risk. When risk is high, coronary revascularization is warranted. When symptoms persist, revascularization is warranted. And, if revascularization is to be considered for any patient, coronary arteriography is a requirement. Although noninvasive means may someday supplant the coronary arteriogram as the gold standard for defining the structural condition of the coronary arteries, for the foreseeable future the appropriate use of coronary arteriography as a diagnostic test should remain.
